Serina Therapeutics, Inc. (SER) AMEX
1.34
-0.12(-8.22%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.34
-0.12(-8.22%)
Currency In USD
Address
601 Genome Way
Huntsville, AL 35806
United States of America (the)
Phone
256 327 9630
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
January 21, 2000
| Name | Title | Pay | Year Born |
| Steven A. Ledger | CEO & Director | 471,199 | 1959 |
| J. Milton Harris | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board | 26,504 | 1941 |
| Balkrishan Gill | Executive Chairman | 215,833 | 1965 |
| Gregory S. Curhan | Chief Financial Officer | 252,663 | 1962 |
| Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing & Controls and Formulation | 261,328 | 1962 |
| Randall W. Moreadith | Chief Development Officer | 433,880 | 1955 |
| Joshua Thomas | Head of Chemistry | 0 | N/A |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.